Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Laryngo- Rhino- Otologie|June 16, 2025
[Pre- and Postoperative Standards in Ear Surgery - Internal Survey by the ADANO Otology Working Group]Julia Esser, Thomas Zahnert, Kristen Rak, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|May 29, 2025
Short-term audiological outcomes of the mCLIP ARC ball joint prosthesis- a retrospective multicenter studyDirk Beutner, N Bevis, S Arndt, et al.
International Journal of Cancer|October 28, 2018
Upregulation of AKR1C1 and AKR1C3 expression in OPSCC with integrated HPV16 and HPV-negative tumors is an indicator of poor prognosisChristian U Huebbers, Femke Verhees, Leonard Poluschkin, et al.
Oncoimmunology|February 7, 2019
Tumor-associated B cells and humoral immune response in head and neck squamous cell carcinomaAxel Lechner, Hans A Schlößer, Martin Thelen, et al.
Audiology & Neuro-Otology|September 10, 2018
Minimal Reporting Standards for Active Middle Ear Hearing ImplantsHannes Maier, Uwe Baumann, Wolf-Dieter Baumgartner, et al.
Oncoimmunology|December 15, 2018
B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodiesHans A Schlößer, Martin Thelen, Axel Lechner, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|April 12, 2019
Hypersalivation: update of the German S2k guideline (AWMF) in short formArmin Steffen, Wolfgang Jost, Tobias Bäumer, et al.
Laryngo- Rhino- Otologie|June 6, 2019
[Hypersalivation - Update of the S2k guideline (AWMF) in short form]Armin Steffen, Wolfgang Jost, Tobias Bäumer, et al.
Blood|September 30, 2022
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLLJohanna Stachelscheid, Qu Jiang, Christoph Aszyk, et al.
NPJ Precision Oncology|June 17, 2021
Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapyMartin Thelen, Kerstin Wennhold, Jonas Lehmann, et al.
Pageof 16